Poly Medicure Limited

rs,

: - 531768 The Manager, BSE Limited, Department of Corporate Services, Phirozee Jeejeebhoy Towers, Dalal Street, Mumbai- 400001. Sub: Submission of Investor’s Presentation Dear Sir/Madam, 'i ’

,%

ates Standalone Performance Summary Q4 FY26 & O9M FY26 Figs in Rs. Crs unless spocified Margin,% Revenue Gross Profit Operating EBITDA' 443.0 olo y a21.0 g 1,662.5 W8T 1,601.8

65.8%

fit Operating EBITDA' 443.0 olo y a21.0 g 1,662.5 W8T 1,601.8 | | 2771 \ ' 65.8% oo 1 2952 o) "/T | — 'i 1] 66.6% | 1 1 1 " 1 1 1 1 ! ! 1 1 1 ! 1 1 1Q4FY2

66.6%

a21.0 g 1,662.5 W8T 1,601.8 | | 2771 \ ' 65.8% oo 1 2952 o) "/T | — 'i 1] 66.6% | 1 1 1 " 1 1 1 1 ! ! 1 1 1 ! 1 1 1Q4FY26 | 66.8% 1—= 'i 68.1% | 1| 1 1

66.8%

1 2952 o) "/T | — 'i 1] 66.6% | 1 1 1 " 1 1 1 1 ! ! 1 1 1 ! 1 1 1Q4FY26 | 66.8% 1—= 'i 68.1% | 1| 1 1 1 1 1,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas

68.1%

| — 'i 1] 66.6% | 1 1 1 " 1 1 1 1 ! ! 1 1 1 ! 1 1 1Q4FY26 | 66.8% 1—= 'i 68.1% | 1| 1 1 1 1 1,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1

5.8%

1 1 1 1 ! ! 1 1 1 ! 1 1 1Q4FY26 | 66.8% 1—= 'i 68.1% | 1| 1 1 1 1 1,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.

27.6%

| 1 1 1 1 1,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.8% ol [N 121.1 116.2 | A o 0% 446.1 4459 ¥ Q4FY25 Q4 FY26

27.3%

1 1 1,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.8% ol [N 121.1 116.2 | A o 0% 446.1 4459 ¥ Q4FY25 Q4 FY26 FY25

27.8%

,070.0_5.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.8% ol [N 121.1 116.2 | A o 0% 446.1 4459 ¥ Q4FY25 Q4 FY26 FY25 FY26

26.8%

.8%1»1,132.0 | ! ! ! 1 1 1 1 1 1 1 U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.8% ol [N 121.1 116.2 | A o 0% 446.1 4459 ¥ Q4FY25 Q4 FY26 FY25 FY26 Q4 FY25

0%

U bvas EY25 ! 1 1 ‘ 27.6% 27.3% 27.8% 26.8% ol [N 121.1 116.2 | A o 0% 446.1 4459 ¥ Q4FY25 Q4 FY26 FY25 FY26 Q4 FY25 Q4FY26 FY25 FY26 Q4 FY25 No of

“have contributed partially to the financial performance of FY26.”

“Naresh Vijayvergiya is an accomplished finance executive with 22+ years of experience foundation and continues to provide strategic culminating in CFO and President-level roles, guidance with an experience of 56 years.”

Less

1

Polymed Group

1

Less

- Cash & Cash equivalent ) - Assets yet to be capitalized or unutilized* - Investment in Subsidiaries/ associates Invested Capital (A) PBT Interest Expense Income on Liquid Investments (cash and cash equivalents above) EBIT (B) Return on Invested Capital (B/A) *includes CWIP, landbank currently unutilised 3,052.7 2484 3,301.1 796.8 146.3 503.3 1,854.7 4479 : 12.9 (67.3) 393.3 15 2,744.2 169.9 2,914.1 1,218.8 89.5 63.4 1,542.5 442.9 : 10.2 (58.9) Given high capex and investment phase for Polymed, evaluating business performance on balance sheet level ROCE may not be relevant due to large undeployed capital * Acquisitions made during the FY26 only . . have contributed partially to the financial performance of FY26. * Given above points, computing ROIC (“Return on Invested Capital”) is a better metric to evaluate financial performance ) ) * Despite low growth in FY 26, ROIC 394.1 continues to remain in excess of 20% 32|POLYMED Shareholding Pattern as on 31st Mar 2026 Bodies Corporate, 2.5

Polymed Group

AUnique Medical Devices Platform 13 ‘ 225+ ‘ Specialities Medical Devices @ 1 25+ \y Countries é§53300+ Employee Base 390+ Patents Granted E | l l f m m,fi’l 5 ““""l Manufacturing Plants Across 5 countries Q 570+ @ Sales Associates Voim 211000+ ; r 7 Distributors across India & Globally 1.8 Billion+ Devices Manufacturing @ Capacity Per year gLargest Exporter argest exporter of Consumable Medical Devices for 10 years inarow 18 32|POLYMED Polymed Flywheel Clinical Engagement 60+ clinical experts; 4,000+ annual customer engagement programs globally In-House Product R&D + 390+ patents; 35 new products launches + ~90 R&D professionals in India and Europe Distribution Network + 1000+ distributors globally » Supplying across 125+ countries Sales & Marketing ; 570+ direct-sales reps in India, Us, Italy, Mexico Expanding presence in other key markets . ) Tooling , Automation, rapid prototyping In-house tool design capability providing faster product launches — @ kfl Manufacturing, Packaging and S